10.6084/m9.figshare.5972563.v1
D Kylhammar
D
Kylhammar
R Hesselstrand
R
Hesselstrand
S Nielsen
S
Nielsen
C Scheele
C
Scheele
G Rådegran
G
Rådegran
Angiogenic and inflammatory biomarkers for screening and follow-up in patients with pulmonary arterial hypertension
Taylor & Francis Group
2018
SSc patients
tumour necrosis factor -α
SSc-associated PAH
growth factor receptor
treatment response
PAH diagnosis
VEGF-A
VEGF-D
Plasma levels
Plasma sVEGFR
placenta growth factor
TNF
biomarker
plasma samples
2018-03-12 14:30:29
Journal contribution
https://tandf.figshare.com/articles/journal_contribution/Angiogenic_and_inflammatory_biomarkers_for_screening_and_follow-up_in_patients_with_pulmonary_arterial_hypertension/5972563
<p><b>Objective</b>: To identify circulating angiogenic and inflammatory biomarkers with potential in screening for pulmonary arterial hypertension (PAH) in systemic sclerosis (SSc), and in early diagnosis and determination of treatment response in PAH.</p> <p><b>Method</b>: Plasma samples were taken at the time of PAH diagnosis and at treatment follow-up after a median (interquartile range) of 4 months (3–9.8 months) in idiopathic (n = 9) and SSc-associated PAH (n = 11). In patients with SSc-associated PAH, plasma samples had also been gathered a median of 2 years (0.8–3 years) before PAH diagnosis (n = 10). Additional plasma samples were retrieved at two time-points separated by a median of 12 years (10–13 years) from SSc patients who did not develop PAH (n = 10) and from controls (n = 8). Angiogenic and inflammatory biomarkers were analysed by multiplex immunoassays.</p> <p><b>Results</b>: Plasma levels of placenta growth factor (PlGF), soluble vascular endothelial growth factor receptor-1 (sVEGFR-1), and tumour necrosis factor-α (TNF-α) were higher (p < 0.05) in SSc patients who later developed PAH than in those who did not. Plasma vascular endothelial growth factor (VEGF)-D increased (p < 0.05) in SSc patients as PAH developed. Plasma levels of PlGF, VEGF-A, VEGF-D, sVEGFR-1, interleukin-6, and TNF-α were higher (p < 0.05) in PAH than controls. There were no significant differences in circulating biomarkers between idiopathic and SSc-associated PAH. Plasma sVEGFR-1 decreased (p < 0.05) after initiating PAH-targeted treatments.</p> <p><b>Conclusions</b>: Plasma levels of PlGF, sVEGFR-1, TNF-α, and VEGF-D have potential in screening for SSc-associated PAH. Plasma sVEGFR-1 may be a biomarker of treatment response.</p>